Antonella Lucia Marretta
Overview
Explore the profile of Antonella Lucia Marretta including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
43
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Parola S, Oing C, Rescigno P, Feliciano S, Carlino F, Pompella L, et al.
Front Genet
. 2024 Dec;
15:1480417.
PMID: 39678373
Testicular germ cell tumors (TGCTs), the most common malignancies affecting young men, are characterized by high sensitivity to cisplatin-based chemotherapy, which leads to high cure rates even in metastatic disease....
2.
Bracigliano A, Marretta A, Guerrera L, Simioli R, Clemente O, Granata V, et al.
Pharmaceuticals (Basel)
. 2024 Mar;
17(3).
PMID: 38543140
Pheochromocytomas (PCCs) and Paragangliomas (PGLs), commonly known as PPGLs to include both entities, are rare neuroendocrine tumors that may arise in the context of hereditary syndromes or be sporadic. However,...
3.
Cannella L, Della Monica R, Marretta A, Iervolino D, Vincenzi B, De Chiara A, et al.
Cells
. 2023 Jun;
12(12).
PMID: 37371106
Dacarbazine is an important drug in the therapeutic landscape of leiomyosarcoma (LMS). Alkylating agents are subjected to resistance mechanisms based on anti-apoptotic pathways and repair mechanisms, including the DNA repair...
4.
Marretta A, Ottaiano A, Iervolino D, Bracigliano A, Clemente O, Di Gennaro F, et al.
J Clin Med
. 2023 Feb;
12(4).
PMID: 36836029
Introduction: Peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE and 90Y-DOTATOC showed efficacy in the metastatic setting of pheocromocytomas (PCCs) and paragangliomas (PGLs) where no standard therapies have been established. Background:...
5.
Marretta A, Di Lorenzo G, Ribera D, Cannella L, von Arx C, Bracigliano A, et al.
Pharmaceutics
. 2021 Sep;
13(9).
PMID: 34575598
Nucleocytoplasmic transport has been found dysregulated in many types of cancer and is often described as a poor prognostic factor. Specifically, Exportin-1 (XPO1) has been found overexpressed in many tumors...
6.
Di Lorenzo G, Zappavigna S, Crocetto F, Giuliano M, Ribera D, Morra R, et al.
Clin Genitourin Cancer
. 2021 May;
19(5):e286-e298.
PMID: 33958297
Introduction: Metastatic castration-resistant prostate cancer (mCRPC) is a deadly disease. Enzalutamide is an oral second-generation anti-androgen that is active in mCRPC. Circulating tumor cells (CTC) count correlates with overall survival...
7.
Ottaviano M, Curvietto M, Rescigno P, Tortora M, Palmieri G, Giannarelli D, et al.
J Immunother Cancer
. 2020 Oct;
8(2).
PMID: 33060148
Background: The coronavirus disease 2019 (COVID-19) pandemic has overwhelmed the health systems worldwide. Data regarding the impact of COVID-19 on cancer patients (CPs) undergoing or candidate for immune checkpoint inhibitors...